Billy Amzal

Challenges for Optimizing Real-World Evidence in Alzheimer’s Disease: The ROADMAP Project

John Gallacher, Andrew Turner, Jacoline C. Bouvy, 2018, Journal of Alzheimer's disease : JAD.

Pragmatic Multicriteria Decision Analysis (MCDA) Combined With Advanced Pharmacoepidemiology for Benefit-Risk Assessments of Medicines Adapted to the Real-Life Constraints of Regulators: Development and Case Study

Mateusz Nikodem, Mireille M Goetghebeur, Alain Micaleff, 2016, Therapeutic innovation & regulatory science.

Impact of increased influenza vaccination in 2–3-year-old children on disease burden within the general population: A Bayesian model-based approach

Billy Amzal, B. Blak, B. Amzal, 2017, PloS one.

Use of historical control data for assessing treatment effects in clinical trials

Fang Chen, Satrajit Roychoudhury, Beat Neuenschwander, 2014, Pharmaceutical statistics.

An Indirect Comparison of Everolimus Versus Axitinib in US Patients With Advanced Renal Cell Carcinoma in Whom Prior Sunitinib Therapy Failed.

Billy Amzal, Zhimei Liu, E. Calvo, 2015, Clinical therapeutics.

Sequential Updating of a New Dynamic Pharmacokinetic Model for Caffeine in Premature Neonates

Frédéric Y. Bois, Pierre Tourneux, Billy Amzal, 2007, Clinical pharmacokinetics.

Combining analytical techniques, exposure assessment and biological effects for risk assessment of chemicals in food

Philippe Verger, Billy Amzal, Pietro Ferrari, 2009 .

Bayesian-Optimal Design via Interacting Particle Systems

Christian P. Robert, Frédéric Y. Bois, Eric Parent, 2006 .

Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial.

Antonio Alcaraz, Jens Rassweiler, Christian Gratzke, 2017, The Lancet. Oncology.